Cognitive Outcomes in Cancer: Recent Advances and Challenges

Dear Colleagues,

Cancer-related cognitive impairment (CRCI), formerly known as ‘chemobrain’, is a prevalent, bothersome, and potentially debilitating problem for survivors for their lifespan. Despite its prevalence, research is relatively limited, and questions remain regarding associated risk factors, underlying mechanisms, and potential interventions to address CRCI. Research is needed to fully understand patients most at risk for CRCI for informed decision-making. Studies which also identify underlying mechanisms are required for the development of evidence-based interventions to manage CRCI. Finally, comprehensive randomized controlled pharmacological and non-pharmacological intervention trials are needed to fully address and mitigate the impact of CRCI on health-related quality of life (psychological, social, financial, academic, vocational, and physical outcomes) of cancer survivors. 

In this Special Issue, we welcome original research articles and reviews that address recent advances in cancer-related cognitive impairment. We especially look for papers that provide insight to the underlying mechanisms, measurement, and new or emerging therapies to address CRCI and its ramifications.

We encourage contributions that are focused on, but not limited to, the following themes:

• Biomarkers;
• Genetic markers;
• Associated Risk Factors including social determinants of health and/or vulnerable populations (e.g., children, adolescent and young adults, and older cancer survivors);
• Neuroimaging;
• Cognitive Rehabilitation—Cognitive Training, Cognitive Behavioral Therapy, etc.
• Stress-reducing therapies—Mindfulness-based stress reduction, exercise, etc.
• Pharmacological interventions;
• Impact on health-related quality of life (psychological, social, financial, academic, vocational, and physical outcomes).

We look forward to receiving your contributions.

Prof. Dr. Diane Von Ah
Prof. Dr. Alexandre Chan
Prof. Dr. Brenna C. McDonald
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.